Milnacipran Arrow (Milnacipran Hydrochloride)

Milnacipran blocks the reuptake transporters for serotonin (SERT) and norepinephrine (NET) on presynaptic neurons. By inhibiting these transporters, it raises the concentration of both neurotransmitters in the synaptic cleft, enhancing neurotransmission in pathways that regulate mood and emotional response.

The specific dose of Milnacipran Arrow is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for milnacipran in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Milnacipran is an SNRI, distinguishing it from selective serotonin reuptake inhibitors (SSRIs) that target only serotonin. Compared with SSRIs, milnacipran may have a more pronounced effect on energy and pain perception, but the safety and efficacy profile should be evaluated individually by the prescriber.

Milnacipran Arrow should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight to maintain product stability.

Milnacipran Arrow is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include elevated blood pressure, tachycardia, serotonin syndrome when combined with other serotonergic drugs, and the potential for worsening depression or suicidal thoughts, especially during early treatment or dose changes.

Milnacipran is contraindicated in patients who have taken a monoamine oxidase inhibitor (MAOI) within the past 14 days, those with uncontrolled hypertension, severe liver impairment, or a known hypersensitivity to milnacipran or any of its excipients.